Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: Relationship to cataplexy and HLA DQB1*0602 Status

Sleep

Volumn 25, Issue 7, 2002, Pages 733-736

  Krahn, Lois E ^a   Pankratz, V Shane ^a   Oliver, Lawrence ^a   Boeve, Bradley F ^a   Silber, Michael H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cataplexy; Cerebrospinal; Hypocretin; Narcolepsy; Orexin

Indexed keywords

HLA DQB1 ANTIGEN; OREXIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CATAPLEXY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; NARCOLEPSY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SLEEP DISORDER;

EID: 0036838860     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/25.7.733     Document Type: Article

References (20)

1. Krahn L, Black J, Silber M. Narcolepsy: New understanding of irresistible sleep. Mayo Clinic Proc 2001;76:185-94
2. Silber M, Krahn L, Olson E, Pankratz V. The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep 2002;25:197-202
3. Broughton R, Guberman A, Roberts J. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: A controlled study. Epilepsia 1984;25:423-33
4. Nishino S, Ripley B, Overeem S, Lammers G, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
5. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8
6. Dalal M, Schuld A, Haack M, et al. Normal plasma levels of orexin A (hypocretin 1) in narcoleptic patients. Neurology 2002;58:334
7. Kastin A, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999;289:219-23
8. Peyron C, Faraco J, Rogers W, et al. A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7
9. Thannickal T, Moore R, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74
10. Mignot E, Lin X, Arrigoni J. DQB1*0602 and DQA1*Q102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep 1994;17:S60-7
11. Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2000;117:9-20
12. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin levels in various neurologic conditions: Low levels in narcolepsy and Guillain-Barré syndrome. Sleep 2001;24:A322
13. Kanbayashi T, Inque Y, Chiba S, et al. CSF hypocretin-1 (orexinA) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-3
14. Anic-Labat S, Guilleminault C, Kraemer H, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87
15. Gowda A, Krahn L, Slocumb N, Lymp J, Moore W, Silber M. Experiences that trigger cataplexy. Sleep 2001;24:A327
16. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8
17. Krahn L, Boeve B, Olson E, Herold D, Silber M. A standardized test for cataplexy. Sleep Med 2000;1:125-30
18. Mignot E, Young T, Lin L, Finn L. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 1999;22:347-52
19. Overeem S, Mignot E, Gert van Dijk J, Lammers G. Narcolepsy: Clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105
20. Hartwig G, Harsh J, Ripley B, Nishino S, Mignot E. Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. Sleep Med 2001;2:451-3